Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD) clinical study in collaboration with the University of Athens, marking an important step in its 2026 multi-center MRD validation program. The study will evaluate the clinical utility and prognostic performance of the company’s proprietary TeloView®MRD assay in multiple myeloma (MM), using well-characterized patient samples with long-term clinical follow-up and existing comparative MRD data.
Science Significance
From a scientific perspective, the study addresses a central challenge in modern oncology: detecting residual cancer cells at extremely low levels with high clinical relevance. TeloView®MRD is designed to detect one myeloma cell among up to ten million blood cells, exceeding the sensitivity typically achieved by current blood-based approaches. Beyond enumeration, the assay uniquely evaluates the three-dimensional genomic architecture of individual MRD cells, offering biological insight into disease aggressiveness and relapse risk. By comparing results with Next-Generation Flow (NGF) across matched blood and bone marrow samples, the study aims to generate robust evidence on how advanced telomere analytics may enhance MRD interpretation beyond conventional cell-counting methods.
Regulatory Significance
The study’s timing is particularly relevant in light of evolving regulatory expectations around MRD. In 2024, the U.S. FDA’s Oncologic Drugs Advisory Committee unanimously supported MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies. As regulators increasingly recognize MRD as a surrogate marker for long-term outcomes, assays such as TeloView®MRD may play a growing role in clinical trials, post-marketing studies, and regulatory submissions. The retrospective Athens study strengthens the clinical evidence base required to support future regulatory engagement and broader clinical adoption.
Business Significance
Advertisement
For Telo Genomics, the Athens collaboration reinforces its strategy to build a large, multi-center clinical validation dataset supporting differentiation of its technology. Access to samples with approximately three years of patient follow-up enhances the assay’s value proposition by linking MRD findings to real-world relapse outcomes. As the global MRD testing market is projected to grow rapidly, driven by oncology drug development and personalized medicine, successful validation could position TeloView®MRD as a high-impact diagnostic tool for pharmaceutical partners, academic centers, and clinical laboratories seeking scalable, less invasive MRD solutions.
Patients’ Significance
For patients with multiple myeloma, the implications are substantial. MM remains an incurable but increasingly manageable blood cancer, with most patients eventually experiencing relapse. Current MRD testing often relies on invasive bone marrow biopsies, which are uncomfortable, costly, and difficult to repeat frequently. A highly sensitive blood-based MRD test could enable more frequent monitoring, earlier detection of relapse risk, and better-informed treatment decisions. This approach aligns with the growing emphasis on patient-friendly, minimally invasive diagnostics that support long-term disease management.
Policy Significance
At the policy level, advances in MRD testing intersect with broader healthcare priorities around precision oncology, value-based care, and accelerated access to innovative therapies. Reliable MRD assays can support faster drug approvals, optimize treatment duration, and potentially reduce unnecessary exposure to costly therapies. As health systems grapple with the rising economic burden of cancer care, blood-based MRD tools may contribute to more efficient resource utilization while improving outcomes.
Overall, the launch of Telo Genomics’ retrospective MRD study with the University of Athens represents a strategic and scientific milestone in the evolution of blood-based MRD assessment for multiple myeloma. By combining ultra-sensitive detection, advanced genomic analytics, and multi-center clinical validation, Telo aims to help redefine how residual disease is measured and acted upon in oncology. As evidence from this and other studies accumulates, TeloView®MRD may emerge as a clinically meaningful bridge between diagnostics, therapeutics, and personalized cancer care.
Source: Telo Genomics Corp press release
